Halozyme Therapeutics (HALO) announced that Janssen Biotech, Inc. (JNJ) has received U.S. Food and Drug Administration approval of DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed light chain amyloidosis. DARZALEX FASPRO is the first and only FDA-approved treatment for patients with this rare and serious blood disorder associated with the production of an abnormal protein which leads to the deterioration of vital organs, most notably the heart, kidneys and liver.1 This indication is approved under accelerated approval and is based on the combination's hematologic complete response rate measure. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials.

Hilltop Holdings (HTH) will replace YETI Holdings (YETI) in the S&P SmallCap 600 as Yeti is replacing Trimble (TRMB) in the S&P MidCap 400.

YETI Holdings (YETI) will replace Trimble (TRMB) in the S&P MidCap 400 as Trimble is replacing Concho Resources (CXO) in the S&P 500.

NTN Buzztime announced it received a letter from the NYSE Regulation stating that it is not in compliance with NYSE American LLC continued listing standards. Specifically, the company is not in compliance with Section 704 of the NYSE American Company Guide because it did not hold an annual meeting during the fiscal year ended December 31, 2020.

In a regulatory filing, Cloudera disclosed that its CEO Robert Bearden sold 141.8K shares of common stock on January 14th in a total transaction size of $2.03M, reducing his stake by about 18%.

Lockheed Martin was awarded a sole-source, cost-plus-incentive-fee, cost-plus-fixed-fee, firm-fixed-price definite contract under a Foreign Military Sales, or FMS, case to the United Arab Emirates, or UAE. The total value of this contract is $254.71M. Under this follow-on contract, the contractor will provide maintenance and sustainment for two Terminal High Altitude Area Defense batteries for UAE. The maintenance and sustainment scope of work includes providing logistics management, logistics product database, training, missile and ground repair and return, hardware/software development and sustainment, hardware in the loop, engineering services, missile field surveillance program and country unique specialty engineering for FMS client. The performance period is from January 15 through January 14, 2026. One offer was solicited and one offer was received. UAE FMS funds in the amount of $254,708,912 will be used to fund this effort. The Missile Defense Agency is the contracting activity.